scholarly journals Vocal Cord Paralysis after Stereotactic Body Radiation Therapy to the Left Lung Apex

2014 ◽  
Vol 9 (11) ◽  
pp. e80-e81
Author(s):  
Todd J. Carpenter ◽  
Kenneth E. Rosenzweig
2016 ◽  
Vol 15 (4) ◽  
pp. 405-407 ◽  
Author(s):  
Yusef A. Syed ◽  
Sung Jun Ma ◽  
Jorge Gomez

AbstractAimWe report a unique presentation of a late side effect associated with stereotactic body radiation therapy (SBRT) of the lung.SummaryThe case of a 65-year-old male who developed left-sided vocal cord paralysis after two courses of SBRT for squamous cell lung carcinoma is presented. The patient developed this late toxicity 15 months after his second treatment, which was to address a recurrence in the perihilar region of the left upper lobe.


Author(s):  
Cecilia Tetta ◽  
Maria Carpenzano ◽  
Areej Tawfiq J Algargoush ◽  
Marwah Algargoosh ◽  
Francesco Londero ◽  
...  

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.


2013 ◽  
Author(s):  
Simon Lo ◽  
Bin S Teh ◽  
Nina A Mayr ◽  
Mitchell Machtay

Sign in / Sign up

Export Citation Format

Share Document